These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38526855)

  • 1. Genetic determinants of taxane-induced peripheral neuropathy.
    Mladosievicova B; Jablonicka MN; Tatayova L; Bernadic M
    Bratisl Lek Listy; 2024; 125(4):207-210. PubMed ID: 38526855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining risks of taxane neuropathy: insights from randomized clinical trials.
    Kudlowitz D; Muggia F
    Clin Cancer Res; 2013 Sep; 19(17):4570-7. PubMed ID: 23817688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expert consensus on standardized management of taxane-related peripheral neuropathy].
    Taxane-related Peripheral Neuropathy Standardized Management Group
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):170-179. PubMed ID: 32252195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer.
    Pabst L; Velten M; Fischbach C; Kalish M; Pflumio C; Pivot X; Petit T
    Breast J; 2020 Dec; 26(12):2376-2382. PubMed ID: 33307596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment.
    Tamburin S; Park SB; Alberti P; Demichelis C; Schenone A; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S40-S51. PubMed ID: 31647157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
    Sodhi M; Yeung SN; Maberley D; Mikelberg F; Etminan M
    JAMA Ophthalmol; 2022 Sep; 140(9):880-884. PubMed ID: 35951320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer.
    Song SJ; Min J; Suh SY; Jung SH; Hahn HJ; Im SA; Lee JY
    Support Care Cancer; 2017 Jul; 25(7):2241-2248. PubMed ID: 28204996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms of lysophosphatidic acid receptor 1 are associated with the onset of taxane-induced peripheral neuropathy.
    Tsuchida R; Tanabe Y; Nishizawa D; Ikeda K; Abe H; Inoue R; Kurano M; Yatomi Y; Tamura K; Takano T; Shimizu C; Uchida K; Sumitani M
    Br J Anaesth; 2021 Aug; 127(2):e43-e46. PubMed ID: 34024637
    [No Abstract]   [Full Text] [Related]  

  • 9. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
    Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
    Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features of taxane neuropathy.
    Kudlowitz D; Muggia F
    Anticancer Drugs; 2014 May; 25(5):495-501. PubMed ID: 24300917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study Protocol.
    Sharma A; Johnson KB; Bie B; Rhoades EE; Sen A; Kida Y; Hockings J; Gatta A; Davenport J; Arcangelini C; Ritzu J; DeVecchio J; Hughen R; Wei M; Thomas Budd G; Lynn Henry N; Eng C; Foss J; Rotroff DM
    Technol Cancer Res Treat; 2022; 21():15330338221127169. PubMed ID: 36172750
    [No Abstract]   [Full Text] [Related]  

  • 12. GM1 for taxane-induced neuropathy in breast cancer.
    Das M
    Lancet Oncol; 2019 Jul; 20(7):e348. PubMed ID: 31130320
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk factors for taxane-induced peripheral neuropathy in patients with breast cancer.
    Liang C; Zhang Y; Chen QY; Chen WF; Chen MZ
    Asia Pac J Clin Oncol; 2024 Apr; 20(2):220-227. PubMed ID: 36658674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study.
    Kus T; Aktas G; Kalender ME; Sevinc A; Kul S; Suner A; Ulker E; Camci C
    Support Care Cancer; 2016 Mar; 24(3):1175-9. PubMed ID: 26279147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
    Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
    JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole genome sequencing across clinical trials identifies rare coding variants in GPR68 associated with chemotherapy-induced peripheral neuropathy.
    Khan Z; Jung M; Crow M; Mohindra R; Maiya V; Kaminker JS; Hackos DH; Chandler GS; McCarthy MI; Bhangale T
    Genome Med; 2023 Jun; 15(1):45. PubMed ID: 37344884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.
    Hertz DL
    Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):227-239. PubMed ID: 33401943
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuropathic Pain in Taxane-Induced Peripheral Neuropathy: Evidence for Exercise in Treatment.
    Andersen Hammond E; Pitz M; Shay B
    Neurorehabil Neural Repair; 2019 Oct; 33(10):792-799. PubMed ID: 31342880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study.
    Wang YJ; Chan YN; Jheng YW; Wu CJ; Lin MW; Tseng LM; Tsai YF; Liu LC
    Support Care Cancer; 2021 Jun; 29(6):2959-2971. PubMed ID: 33025227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.